Head to Head Contrast: Kymera Therapeutics (NASDAQ:KYMR) & GRAIL (NASDAQ:GRAL)

Kymera Therapeutics (NASDAQ:KYMR) and GRAIL (NASDAQ:GRAL) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Analyst Ratings

This is a summary of current ratings and price targets for Kymera Therapeutics and GRAIL, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1	2	23	1	2.89
GRAIL	1	6	5	0	2.33

Kymera Therapeutics currently has a consensus target price of $134.68, suggesting a potential upside of 18.70%. GRAIL has a consensus target price of $119.80, suggesting a potential downside of 3.91%. Given Kymera Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Kymera Therapeutics is more favorable than GRAIL.

Volatility & Risk

Kymera Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, GRAIL has a beta of 2.83, indicating that its stock price is 183% more volatile than the S&P 500.

Valuation and Earnings

This table compares Kymera Therapeutics and GRAIL”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21 million	240.61	-$311.35 million	($3.24)	-35.02
GRAIL	$147.17 million	37.84	-$408.35 million	($9.75)	-12.79

Kymera Therapeutics has higher earnings, but lower revenue than GRAIL. Kymera Therapeutics is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kymera Therapeutics and GRAIL’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
GRAIL	-236.95%	-15.88%	-14.02%

Summary

Kymera Therapeutics beats GRAIL on 7 of the 13 factors compared between the two stocks.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About GRAIL

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.